Clinical Analysis: Should This Patient Switch to Dapagliflozin 10 mg + Metformin 500 mg?

Quick Patient Summary

• 55-year-old female, T2DM, well controlled on Metformin 1000 mg OD at night
• Hypertension: BP 120/80 on Telmisartan 20 mg (well controlled)
• Complaint: Diarrhea 2x/week (likely metformin GI side effect)
• Good renal function | Mild LFT derangement

Step 1: Is the Diarrhea Definitely from Metformin?

• IBS, infections, other medications
• Telmisartan rarely causes diarrhea but worth reviewing
• Dietary changes

Step 2: Before Switching - Try These First (ADA 2025 & Clinical Evidence)

The 2021 meta-analysis (PMID: 33887354) found metformin XR had similar overall GI side effect rates to IR, but reduced dyspepsia specifically. So XR is worth trying if not already on it.

Step 3: Is Switching to Dapagliflozin 10 mg + Metformin 500 mg Necessary by Guidelines?

ADA 2025 Standards of Care - Key Recommendations

• There is established ASCVD or high cardiovascular risk (Rec 9.10)
• There is heart failure (HFrEF/HFpEF)
• There is CKD with proteinuria
• There is obesity requiring weight loss (SGLT2i provides intermediate weight reduction)

However, there ARE valid reasons to consider the combination:

1. Metformin GI intolerance - If simple measures fail, reducing metformin to 500 mg and adding dapagliflozin 10 mg is a clinically reasonable strategy (combination allows lower metformin dose while maintaining glycemic control)
2. Cardiovascular and renal protection - Dapagliflozin adds cardiorenal benefits even without established disease (primary prevention benefit)
3. BP lowering - SGLT2 inhibitors reduce systolic BP by ~3-5 mmHg (modest osmotic diuresis effect); with this patient already on telmisartan and BP at 120/80, monitor for hypotension, especially with the dual-pathway RAS + SGLT2 effect
4. Weight benefit - SGLT2i provides ~2-3 kg weight loss

Step 4: Pre-Requisites Before Starting Dapagliflozin

1. Renal Function (eGFR)

• Dapagliflozin for glycemic control: eGFR must be ≥45 mL/min/1.73m² (at eGFR <45, glycemic efficacy is limited)
• Dapagliflozin for CKD/CV protection: can be continued down to eGFR 15 or even lower per CREDENCE/DAPA-CKD data
• This patient has good renal function - no concern here. But establish a baseline eGFR before starting and recheck at 4 weeks (an initial 5-8 mL/min/1.73m² dip from reduced hyperfiltration is normal and expected - do not stop the drug for this alone)

2. Liver Function (LFT Mild Derangement)

• Mild hepatic impairment: No dose adjustment needed for dapagliflozin. In mild impairment, AUC increases only ~3% - clinically insignificant (PMC evidence and NICE guidance)
• Moderate impairment: AUC increases 36%, still usually used without dose change
• Severe impairment only: Start at 5 mg, may increase to 10 mg if tolerated
• This patient's mild LFT derangement is NOT a contraindication to dapagliflozin 10 mg

However, determine the cause of the LFT derangement first - NAFLD/MASLD is common in T2DM and dapagliflozin actually has emerging benefit in this condition. Metformin itself can occasionally raise LFTs. Avoid if acute liver disease or severe cirrhosis.

3. Telmisartan Interaction - Blood Pressure Caution

• Both telmisartan (ARB) and dapagliflozin lower blood pressure
• Her BP is already well controlled at 120/80 on telmisartan 20 mg
• Adding dapagliflozin could drop BP further due to osmotic diuresis
• Monitor BP closely in the first 4-6 weeks - watch for symptomatic hypotension (dizziness, lightheadedness, especially on standing)
• The telmisartan dose is relatively low (20 mg), so combined hypotension risk is moderate but not high

4. Urinary and Genital Infection Risk

• SGLT2 inhibitors increase glucosuria, creating a favorable environment for UTIs and genital mycotic infections (particularly in women)
• Assess for recurrent UTIs before initiating
• Counsel the patient on adequate hydration and hygiene

5. DKA Risk Assessment

• Rare in T2DM but possible - do not initiate if patient is volume-depleted, fasting perioperatively, or on very low carb diet
• Instruct patient to hold dapagliflozin 48 hours before any planned surgery or prolonged fasting

6. Volume Status

• Rule out dehydration before starting
• Patient should maintain adequate fluid intake

7. Baseline Tests Required

Summary Recommendation

1. Switch to Metformin XR 1000 mg at night (or split to 500 mg BD with food) - see if diarrhea resolves
2. If diarrhea persists and GI intolerance is confirmed as metformin-related, add dapagliflozin 10 mg and reduce metformin to 500 mg OD
3. Complete pre-requisite workup as listed above before initiating
4. Monitor BP, eGFR, and symptoms at 4 weeks post-initiation

• ADA Standards of Care in Diabetes 2025, Diabetes Care 2025;48(Suppl.1):S181-S206
• Chen S et al. Clin Med Insights Endocrinol Diabetes 2026 - Metformin GI intolerance review [PMID: 42179978]
• Abrilla AA et al. Metformin XR vs IR - systematic review, Diabetes Res Clin Pract 2021 [PMID: 33887354]
• NICE/Cheshire & Merseyside formulary - Dapagliflozin hepatic impairment guidance (July 2025)
• StatPearls SGLT2 inhibitors (updated June 2025) - hepatic/renal use guidance